Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 989-991

  Blum, Shany ^a   Milman, Uzi ^b   Shapira, Chen ^c   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Clinical Pharmacology Institute   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAPTOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 16Q; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; DIABETES MELLITUS; DRUG COST; EDITORIAL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; LIPID OXIDATION; MONOTHERAPY; OXIDATIVE STRESS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PUBLIC HEALTH SERVICE; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; GENOTYPE; HAPTOGLOBINS; HUMANS; PHARMACOGENETICS;

EID: 50149083681     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.989     Document Type: Editorial

References (17)

1. Moreno P, Fuster V: New aspects in the pathogenesis of diabetic atherosclerosis. J. Am. Coll. Cardiol. 44, 2293-2300 (2004).
2. American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care 31, 1-20 (2008).
3. Levy AP, Hochberg I, Jablonski K et al.: Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40, 1984-1990 (2002).
4. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP: Haptoglobin genotype is predictive of major adverse cardiac-events in the one year period after PTCA in individuals with diabetes. Diabetes Care 26, 2628-2631 (2003).
5. Suleiman M, Aronson D, Asleh R et al.: Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 19, 2802-2806 (2005).
6. Milman U. Blum S, Shapira C et al.: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective, double-blinded clinical trial. Arterioscler. Thromb. Vasc. Biol. 28, 341-347 (2008).
7. Costacou T, Ferrell RE, Orchard TJ: Haptoglobin genotype: a determinant of cardiovascular complication risk in Type I diabetes. Diabetes 57(6), 1702-1706 (2008).
8. Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 12, 189-261 (1982).
9. Kristiansen M, Graversen JH, Jacobsen C et al.: Identification of the hemoglobin scavenger receptor. Nature 409, 198-201 (2001).
10. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N: Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43, 3899-3906 (2004).
11. Frank M, Lache O, Enav B et al.: Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood 98, 3693-3698 (2001).
12. Asleh R, Marsh S, Shiltruck M et al.: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92, 1193-1200 (2003).
13. Asleh R, Blum S, Kalet-Litman S et al.: Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes (2008) (Epub ahead of print).
14. Levy AP, Purushothaman KR, Levy NS et al.: Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ. Res. 101, 106-110 (2007).
15. Miller ER, Barriuso RP, Dalal D, Riemersma RA, Appel LJ, Guallar-E: Meta-analysis: high dosage vitamin E supplementation may increase all cause mortality. Ann. Intern. Med. 142, 37-46 (2005).
16. Levy AP, Gerstein H, Lotan R et al.: The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27, 2767 (2004).
17. Blum S, Milman U, Shapira C et al.: Dual therapy with statins and and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler. Thromb. Vasc. Biol. 28, e18-e20 (2008).